» Articles » PMID: 30651930

CD39 Regulatory T Cells Accumulate in Colon Adenocarcinomas and Display Markers of Increased Suppressive Function

Overview
Journal Oncotarget
Specialty Oncology
Date 2019 Jan 18
PMID 30651930
Citations 23
Authors
Affiliations
Soon will be listed here.
Abstract

Increasing knowledge of the function and regulation of tumor-infiltrating lymphocytes has led to new insights in cancer immunotherapy. Regulatory T cells (Treg) accumulate in colon tumors, and we recently showed that CD39 Treg from cancer patients inhibit transendothelial migration of conventional T cells. CD39 mediates the hydrolysis of ATP to immunosuppressive adenosine and adds to the immunosuppressive effects of Treg. Here, we further investigated the regulatory features of intratumoral CD39 Treg in colon cancer. Using flow cytometry analyses of cells from 46 colon cancer patients, we confirm the accumulation of CD39 Treg in the tumor tissue compared to unaffected colon tissue, and also show that tumor-infiltrating Treg express more CD39 and Foxp3 on a per cell basis. Furthermore, CD39 Treg in tumors express markers indicating increased turnover and suppressive ability. In particular, tumor-infiltrating CD39 Treg have high expression of surface molecules related to immunosuppression, such as ICOS, PD-L1 and CTLA-4. Functional suppression assays also indicate potent suppressive capacity of CD39 Treg on proliferation and IFN-γ secretion by conventional T cells. In conclusion, our results identify tumor-infiltrating CD39 Treg as a numerous and potentially important immunosuppressive subset, and suggest that immunotherapy aimed at reducing the activity of CD39 Treg may be particularly useful in the setting of colon cancer.

Citing Articles

Current Landscape of Cancer Immunotherapy: Harnessing the Immune Arsenal to Overcome Immune Evasion.

Mitra A, Kumar A, Amdare N, Pathak R Biology (Basel). 2024; 13(5).

PMID: 38785789 PMC: 11118874. DOI: 10.3390/biology13050307.


In-depth immune profiling of peripheral blood mononuclear cells in patients with pancreatic ductal adenocarcinoma reveals discriminative immune subpopulations.

Rodriguez E, Zwart E, Affandi A, Verhoeff J, de Kok M, Boyd L Cancer Sci. 2024; 115(7):2170-2183.

PMID: 38686549 PMC: 11247553. DOI: 10.1111/cas.16147.


CD8-Targeted IL2 Unleashes Tumor-Specific Immunity in Human Cancer Tissue by Reviving the Dysfunctional T-cell Pool.

Kaptein P, Slingerland N, Metoikidou C, Prinz F, Brokamp S, Machuca-Ostos M Cancer Discov. 2024; 14(7):1226-1251.

PMID: 38563969 PMC: 11215409. DOI: 10.1158/2159-8290.CD-23-1263.


Immune checkpoints are predominantly co-expressed by clonally expanded CD4FoxP3 intratumoral T-cells in primary human cancers.

Bredel D, Tihic E, Mouraud S, Danlos F, Susini S, Aglave M J Exp Clin Cancer Res. 2023; 42(1):333.

PMID: 38057799 PMC: 10699039. DOI: 10.1186/s13046-023-02897-6.


Location of CD39 T cell subpopulations within tumors predict differential outcomes in non-small cell lung cancer.

Koppensteiner L, Mathieson L, Pattle S, Dorward D, OConnor R, Akram A J Immunother Cancer. 2023; 11(8).

PMID: 37648263 PMC: 10471883. DOI: 10.1136/jitc-2023-006770.


References
1.
Lundgren A, Stromberg E, Sjoling A, Lindholm C, Enarsson K, Edebo A . Mucosal FOXP3-expressing CD4+ CD25high regulatory T cells in Helicobacter pylori-infected patients. Infect Immun. 2004; 73(1):523-31. PMC: 538965. DOI: 10.1128/IAI.73.1.523-531.2005. View

2.
Dimberg J, Hugander A, Wagsater D . Protein expression of the chemokine, CCL28, in human colorectal cancer. Int J Oncol. 2006; 28(2):315-9. View

3.
Loddenkemper C, Schernus M, Noutsias M, Stein H, Thiel E, Nagorsen D . In situ analysis of FOXP3+ regulatory T cells in human colorectal cancer. J Transl Med. 2006; 4:52. PMC: 1764431. DOI: 10.1186/1479-5876-4-52. View

4.
Piccirillo C . Regulatory T cells in health and disease. Cytokine. 2008; 43(3):395-401. DOI: 10.1016/j.cyto.2008.07.469. View

5.
Salama P, Phillips M, Grieu F, Morris M, Zeps N, Joseph D . Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer. J Clin Oncol. 2008; 27(2):186-92. DOI: 10.1200/JCO.2008.18.7229. View